Moderna, Inc. MRNA stock is trading lower on Monday. The COVID-19 vaccine maker and Merck & Co Inc. MRK reported five-year ...

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...

Moderna (MRNA) closed at $41.95 in the latest trading session, marking a +2.29% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%. Meanwhile, the Dow ...

NEW YORK - Debate over the need for COVID-19 booster shots is clouding the outlook for Moderna Inc's high-flying shares after ...

Moderna (MRNA) stock pushed meaningfully higher on Friday following reports that the biotech giant is leveraging its mRNA platform to develop a vaccine for hantavirus. The news, which arrived after a ...

The company confirmed early-stage hantavirus research as a WHO-confirmed outbreak grows, while flu vaccine data published in a top medical journal ...

Moderna's shares have performed well this year, driven by clinical and regulatory progress. The company's results being reported on Friday won't be particularly strong, especially as its core market ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...